BioApp was established in 2011 based on POSTECH's plant biotechnology. It has achieved significant milestones, being the first to accomplish various achievements in both Korea and globally. Notably, the HERBAVAC™ CSF Green Marker vaccine, the world's inaugural plant-based classical swine fever vaccine, has been approved. BioApp aims to contribute to eliminating classical swine fever by achieving CSF-free status in Korea and entering the global market.
Beyond animal vaccines, BioApp is engaged in developing vaccines for COVID-19, Zika, and dementia prevention. The company strives to establish a green vaccine production system to ensure swift delivery of secure and efficient vaccines, enhancing vaccine self-sufficiency to safeguard public health from severe infectious diseases.
Company Details
- Employees
- 3
- Founded
- 2011
- Address
- 394, Jigok-Ro, Nam-Gu,pohang-Si,gyeongsangbuk-Do,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Nam-gu, Pohang-si, Gyeongsangbuk-do
Bioapplications Inc. Questions
Bioapplications Inc.'s website is https://www.bioapplications.global/
Bioapplications Inc.'s LinkedIn profile is https://kr.linkedin.com/company/bioapplications-inc
Bioapplications Inc. has
3 employees.
View email and phone details for 3
employees at Bioapplications Inc..
Bioapplications Inc.'s industry is
Biotechnology Research
Bioapplications Inc.'s top competitors are
Bioapp, Llc,
Seawith Inc.,
Cellmeat,
Miruku,
Helixon Us Inc.,
Ilo Social Protection,
Simple Planet,
Mushroom Material,
Metanovas Biotech,
Tissenbiofarm.
Bioapplications Inc.'s categories are Biotechnology Research
Bioapplications Inc.'s founding year is 2011
